IP Library › Granted Patent US 12,226,529
Granted Patent B2
US 12,226,529 · App. 15/755,018 · Granted Feb 18, 2025

Stable nanolipoprotein particles and related compositions methods and systems

Inventors: Craig D. Blanchette (Concord, CA); Nicholas Fischer (Livermore, CA); Sean Fitzpatrick Gilmore (Oakland, CA); Amy Rasley (Livermore, CA); Paul Henderson (Dublin, CA)
Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
A61K9/1273A61K9/1278A61K47/6915A61K49/0086C07F9/106C07K14/705C07K14/775B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,529
App. No.
15/755,018
Granted
Feb 18, 2025
Kind
B2
Abstract

Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and/or one or more polymerizable lipids.

Claims (69)

1. A nanolipoprotein particle comprising:

a membrane forming lipid, a polymerized lipid and a scaffold protein,

the membrane forming lipid and the polymerized lipid arranged in a membrane forming lipid discoidal bilayer stabilized by the scaffold protein and by the polymerized lipid,

wherein the polymerized lipid is formed by crosslinking polymerizable lipids within the membrane forming lipid discoidal bilayer in a molar concentration of about 5 to about 40 mol %.

2. The nanolipoprotein particle of claim 1 , wherein the polymerized lipid is in a molar concentration of about 10 to about 40 mol %.

3. The nanolipoprotein particle of claim 1 , wherein a total lipid to scaffold protein molar percent ratio ranges from 20:1 to 240:1.

4. The nanolipoprotein particle of claim 1 , wherein the membrane forming lipid is in amount from 95 to 60% and the polymerized lipid is in an amount from 5 to 40% with respect to a total lipid concentration.

5. The nanolipoprotein particle of claim 1 , wherein the membrane forming lipid and polymerized lipid are in a molar percent ratio membrane forming lipid: polymerized lipids ranging from 95:5 to 60:40.

6. The nanolipoprotein particle of claim 1 , wherein the polymerizable lipids comprise lipids of Formula (I)

wherein

R1 and R2 are independently selected from C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain, at least one of R1 and R2 present at least one polymerizable functional group;

in which R 11 , R 12 and R 13 are independently H or a C1-C4 branched or straight aliphatic carbon chain;

R 21 is H, OH, or a carboxy group

m=0-3; and

n and o are independently 0 and 1.

7. The nanolipoprotein particle of claim 6 , wherein R1, and R2 present at least two polymerizable functional groups for polymerization with corresponding functional groups within the membrane lipid bilayer.

8. The nanolipoprotein particle of claim 1 , wherein the polymerizable lipids comprise lipids of Formula (VI)

wherein

R 1 , R 2 are independently a C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain;

in which R 11 , R 12 are independently H or a C1-C4 branched or straight aliphatic carbon chain and R3 is a C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain,

n and o are independently 0 and 1;

and wherein at least one of R 1 , R 2 and R 3 comprise at least one polymerizable functional group.

9. The nanolipoprotein particle of claim 8 , wherein at R 1 , R 2 and R 3 present at least two polymerizable functional groups for polymerization with corresponding functional groups within the membrane lipid bilayer.

10. The nanolipoprotein particle of claim 1 , wherein the polymerizable lipids comprise lipids of Formula (X)

wherein

R 4 , R 5 and R 6 are independently C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain, at least one of R 4 , R 5 and R 6 contains at least one polymerizable functional group, and at least one of R 4 , R 5 and R 6 contains at least one amino nitrogen.

11. The nanolipoprotein particle of claim 10 , wherein at least one of R 2 , R 3 and R 4 contains 1-6 units of an ethyleneoxy group —(CH 2 CH 2 O)—.

12. The nanolipoprotein particle of claim 6 , wherein the at least one polymerizable functional group in the polymerizable lipids of Formula (I) is selected from diacetylene groups, methacrylate groups, acryloyl groups, sorbyl ester groups, diene groups, styrene groups, vinyl groups and isocyano groups.

13. The nanolipoprotein particle of claim 1 , wherein the nanolipoprotein particle further comprises one or more functionalized amphipathic compound.

14. The nanolipoprotein particle of claim 13 , wherein the one or more functionalized amphipathic compounds comprise one or more functionalized membrane forming lipids.

15. The nanolipoprotein particle of claim 14 , wherein the one or more functionalized membrane forming lipids is present in 0.1 mol % to 95 mol % relative to polymerized lipid in the membrane lipid bilayer.

16. The nanolipoprotein particle of claim 1 , further comprising one or more membrane proteins attached to the membrane lipid bilayer through interaction of the target protein hydrophobic region with the membrane lipid bilayer.

17. The nanolipoprotein particle of claim 1 , further comprising one or more functional molecules selected from a functional molecule embedded in the membrane lipid bilayer, a functional molecule conjugated to a lipophilic anchor compound inserted into the membrane lipid bilayer and a functional molecule conjugated through binding of a functional group with a corresponding functional group presented on functionalized membrane forming lipid of the membrane lipid bilayer.

18. The nanolipoprotein particle of claim 17 , wherein the one or more functional molecule comprises drug or cellular targeting compound.

19. The nanolipoprotein particle of claim 18 , wherein the drug or cellular targeting compound are in an amount ranging from 0.1-10 mol %.

20. A nanolipoprotein particle comprising a cross-linked membrane lipid bilayer confined in a discoidal configuration by a scaffold protein, the cross-linked membrane lipid bilayer comprising one or more polymerized lipids and one or more membrane forming lipids.

21. The nanolipoprotein particle of claim 20 , wherein the one or more polymerized lipids comprise lipids of Formula (I)

wherein

R 1 and R 2 are independently selected from C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain, at least one of R 1 and R 2 present at least one polymerizable functional group;

in which R 11 , R 12 and R 13 are independently H or a C1-C4 branched or straight aliphatic carbon chain;

R 21 is H, OH, or a carboxy group

m=0-3; and

n and o are independently 0 and;

and wherein the at least one polymerizable functional group binds a corresponding polymerizable functional group in the membrane lipid bilayer providing a polymerized lipid within the membrane lipid bilayer.

22. The nanolipoprotein particle of claim 21 , wherein at least two polymerizable functional group binds a corresponding polymerizable functional group in the membrane lipid bilayer thus providing a polymerized lipid within the membrane lipid bilayer.

23. The nanolipoprotein particle of claim 20 , wherein the one or more polymerized lipids comprise a lipid of Formula (VI)

wherein

R 1 , R 2 are independently a C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain;

in which R 11 , R 12 are independently H or a C1-C4 branched or straight aliphatic carbon chain and R 3 is a C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain,

n and o are independently 0 and 1;

and wherein at least one of R 1 , R 2 and R 3 comprise at least one polymerizable functional group binding a corresponding polymerizable functional group in the membrane lipid bilayer thus providing a polymerized lipid within the membrane lipid bilayer.

24. The nanolipoprotein particle of claim 23 , wherein at least two polymerizable functional group binds a corresponding polymerizable functional group in the membrane lipid bilayer thus providing a polymerized lipid within the membrane lipid bilayer.

25. The nanolipoprotein particle of claim 20 , wherein the one or more polymerizable lipids comprise a lipid of Formula (X)

wherein

R 4 , R 5 and R 6 are independently C7-C29 branched or straight, substituted or unsubstituted aliphatic carbon chain, at least one of R 4 , R 5 and R 6 contains at least one amino nitrogen and at least one of R 4 , R 5 and R 6 contains at least one polymerizable functional group binding a corresponding polymerizable functional group in the membrane lipid bilayer thus providing a polymerized lipid within the membrane lipid bilayer.

26. The nanolipoprotein particle of claim 25 , wherein at least two polymerizable functional group binds a corresponding polymerizable functional group in the membrane lipid bilayer thus providing a polymerized lipid within the membrane lipid bilayer.

27. The nanolipoprotein particle of claim 25 , wherein at least one of R 4 , R 5 and R 6 contains 1-6 units of an ethyleneoxy group —(CH 2 CH 2 O)—.

28. The nanolipoprotein particle of claim 20 , wherein the polymerizable functional group is selected from diacetylene groups, methacrylate groups, acryloyl groups, sorbyl ester groups, diene groups, styrene groups, vinyl groups and isocyano groups.

29. The nanolipoprotein particle of claim 20 , wherein the nanolipoprotein particle further comprises one or more functionalized amphipathic compound.

30. The nanolipoprotein particle of claim 29 , wherein the one or more functionalized amphipathic compound comprise one or more functionalized membrane forming lipids.

31. The nanolipoprotein particle of claim 30 , wherein the one or more functionalized membrane forming lipids is present in 0.1 mol % to 95 mol % relative to polymerized lipid in the membrane lipid bilayer.

32. The nanolipoprotein particle of claim 20 , further comprising one or more membrane proteins attached to the membrane lipid bilayer through interaction of the target protein hydrophobic region with the membrane lipid bilayer.

33. The nanolipoprotein particle of claim 20 , further comprising one or more functional molecules selected from a functional molecule embedded in the membrane lipid bilayer, a functional molecule conjugated to a lipophilic anchor compound inserted into the membrane lipid bilayer and a functional molecule conjugated through binding of a functional group with a corresponding functional group presented on functionalized membrane forming lipid of the membrane lipid bilayer.

34. The nanolipoprotein particle of claim 33 , wherein the one or more functional molecule comprises drug or cellular targeting compound.

35. The nanolipoprotein particle of claim 34 , wherein the drug or cellular targeting compound are in an amount ranging from 0.1-10 mol %.

36. A nanolipoprotein particle comprising:

a membrane forming lipid, a polymerized lipid and a scaffold protein,

the membrane forming lipid and the polymerized lipid arranged in a membrane forming lipid discoidal bilayer stabilized by the scaffold protein and by the polymerized lipid,

wherein the polymerized lipid is formed by crosslinking polymerizable lipids, and wherein the polymerized lipid is in a molar concentration of about 10 to about 30 mol % and a total lipid to scaffold protein molar percent ratio ranges from 20:1 to 240:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2025
From: GILMORE, SEAN FITZPATRICK; HENDERSON, PAUL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 071132/0666 →
CONFIRMATORY LICENSE Recorded Feb 26, 2019
From: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 048436/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2018
From: BLANCHETTE, CRAIG D.; FISCHER, NICHOLAS; RASLEY, AMY
To: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Reel/Frame 045037/0007 →
Continuity (2)
Provisional Application 62209784 · Aug 25, 2015
Related Publication 20190142752A1 · May 16, 2019
References Cited (400)
US 4317771A · Shiba et al. · 1982 [cited by applicant]
US 5374715A · Kanno et al. · 1994 [cited by applicant]
US 5393530A · Schneider · 1995 [cited by applicant]
US 5679559A · Kim et al. · 1997 [cited by applicant]
US 6270649B1 · Zeikus et al. · 2001 [cited by applicant]
US 6365191B1 · Burman et al. · 2002 [cited by applicant]
US 6599527B1 · Leigh et al. · 2003 [cited by applicant]
US 7015471B2 · Franzen et al. · 2006 [cited by applicant]
US 7048949B2 · Sligar et al. · 2006 [cited by applicant]
US 7083958B2 · Sligar et al. · 2006 [cited by applicant]
US 7375234B2 · Sharpless et al. · 2008 [cited by applicant]
US 7575763B2 · Sligar et al. · 2009 [cited by applicant]
US 7592008B2 · Sligar et al. · 2009 [cited by applicant]
US 7622437B2 · Morrissey et al. · 2009 [cited by applicant]
US 7662410B2 · Sligar et al. · 2010 [cited by applicant]
US 7691414B2 · Sligar et al. · 2010 [cited by applicant]
US 7824709B2 · Ryan et al. · 2010 [cited by applicant]
US 8183010B2 · Swartz et al. · 2012 [cited by applicant]
US 8268796B2 · Ryan · 2012 [cited by applicant]
US 8883729B2 · Hoeprich et al. · 2014 [cited by applicant]
US 8889623B2 · Hoeprich et al. · 2014 [cited by applicant]
US 8895055B2 · Lam et al. · 2014 [cited by applicant]
US 8907061B2 · Chromy et al. · 2014 [cited by applicant]
US 9303273B2 · Hoeprich et al. · 2016 [cited by applicant]
US 9388232B2 · Dasseux et al. · 2016 [cited by applicant]
US 9458191B2 · Chromy et al. · 2016 [cited by applicant]
US 9644038B2 · Luo et al. · 2017 [cited by applicant]
US 9688718B2 · Baker et al. · 2017 [cited by applicant]
US 10151037B2 · Hoeprich, Jr. et al. · 2018 [cited by applicant]
US 10934628B2 · Hoeprich, Jr. et al. · 2021 [cited by applicant]
US 11053322B2 · Luo et al. · 2021 [cited by applicant]
US 11207422B2 · Coleman et al. · 2021 [cited by applicant]
US 11279749B2 · Hoeprich, Jr. et al. · 2022 [cited by applicant]
US 11300572B2 · Coleman et al. · 2022 [cited by applicant]
US 20010051131A1 · Unger · 2001 [cited by examiner]
US 20020041898A1 · Unger et al. · 2002 [cited by applicant]
US 20030008014A1 · Shelness · 2003 [cited by examiner]
US 20040101741A1 · Minteer et al. · 2004 [cited by applicant]
US 20040180369A1 · Franzen et al. · 2004 [cited by applicant]
US 20040204354A1 · Nelson et al. · 2004 [cited by applicant]
US 20050182243A1 · Sligar et al. · 2005 [cited by applicant]
US 20050244414A1 · Mundy et al. · 2005 [cited by applicant]
US 20060013885A1 · Nah et al. · 2006 [cited by applicant]
US 20060088524A1 · Morrissey · 2006 [cited by examiner]
US 20060127310A1 · Russell-Jones et al. · 2006 [cited by applicant]
US 20060127467A1 · Watkin · 2006 [cited by applicant]
US 20060189554A1 · Mumper et al. · 2006 [cited by applicant]
US 20060211092A1 · Sligar et al. · 2006 [cited by applicant]
US 20070101448A1 · Anantharamiah et al. · 2007 [cited by applicant]
US 20070117179A1 · Kudlicki et al. · 2007 [cited by applicant]
US 20070287034A1 · Minteer et al. · 2007 [cited by applicant]
US 20080124350A1 · Mumper et al. · 2008 [cited by applicant]
US 20080188399A1 · Sinko et al. · 2008 [cited by applicant]
US 20080248565A1 · Katzen et al. · 2008 [cited by applicant]
US 20090136937A1 · Coleman et al. · 2009 [cited by applicant]
US 20090186393A1 · Baker et al. · 2009 [cited by applicant]
US 20090192299A1 · Chromy et al. · 2009 [cited by applicant]
US 20090203549A1 · Hoeprich, Jr. et al. · 2009 [cited by applicant]
US 20090203706A1 · Zhao et al. · 2009 [cited by applicant]
US 20090270331A1 · Remaley et al. · 2009 [cited by applicant]
US 20090311276A1 · Hoeprich et al. · 2009 [cited by applicant]
US 20090324706A1 · Mirkin et al. · 2009 [cited by applicant]
US 20100092567A1 · Hoeprich et al. · 2010 [cited by applicant]
US 20100158994A1 · Watkin · 2010 [cited by applicant]
US 20100203609A1 · Yacoby et al. · 2010 [cited by applicant]
US 20110059549A1 · Coleman et al. · 2011 [cited by applicant]
US 20110178029A1 · Knudsen et al. · 2011 [cited by applicant]
US 20110178164A1 · Cunha et al. · 2011 [cited by applicant]
US 20110195450A1 · Kudlicki et al. · 2011 [cited by applicant]
US 20110286915A1 · Lam et al. · 2011 [cited by applicant]
US 20120148642A1 · Remaley et al. · 2012 [cited by applicant]
US 20120245101A1 · Anantharamaiah et al. · 2012 [cited by applicant]
US 20130164369A1 · Lam et al. · 2013 [cited by applicant]
US 20130165636A1 · Luo et al. · 2013 [cited by applicant]
US 20140273142A1 · Hoeprich · 2014 [cited by applicant]
US 20140308341A1 · Fujii et al. · 2014 [cited by applicant]
US 20150140108A1 · Peer et al. · 2015 [cited by applicant]
US 20160083858A1 · Hoeprich, Jr. · 2016 [cited by examiner]
US 20160235671A1 · Li et al. · 2016 [cited by applicant]
US 20160324923A1 · Dasseux et al. · 2016 [cited by applicant]
US 20180079829A1 · Luo et al. · 2018 [cited by applicant]
US 20180186860A1 · Hoeprich, Jr. et al. · 2018 [cited by applicant]
US 20180318218A1 · Kamrud et al. · 2018 [cited by applicant]
US 20190055658A1 · Hoeprich, Jr. et al. · 2019 [cited by applicant]
US 20190094230A1 · Coleman et al. · 2019 [cited by applicant]
US 20190307692A1 · Blanchette et al. · 2019 [cited by applicant]
US 20200046848A1 · Coleman et al. · 2020 [cited by applicant]
US 20210317234A1 · Luo · 2021 [cited by applicant]
US 20220283171A1 · Coleman et al. · 2022 [cited by applicant]
EP 3426304A1 · 2019 [cited by applicant]
JP 2008516605A · 2008 [cited by applicant]
JP 2015110677A · 2015 [cited by applicant]
WO 9959550A1 · 1999 [cited by applicant]
WO 0065099A1 · 2000 [cited by applicant]
WO 0240501A2 · 2002 [cited by applicant]
WO 2004094651A2 · 2004 [cited by applicant]
WO 2004112214A2 · 2004 [cited by applicant]
WO 2005070400A1 · 2005 [cited by applicant]
WO 2006073419A2 · 2006 [cited by applicant]
WO 2007038755A1 · 2007 [cited by applicant]
WO 2007050501A2 · 2007 [cited by applicant]
WO 2007053655A2 · 2007 [cited by applicant]
WO 2008028206A2 · 2008 [cited by applicant]
WO 2008106660A2 · 2008 [cited by applicant]
WO 2009100201A2 · 2009 [cited by applicant]
WO 2010039496A2 · 2010 [cited by applicant]
WO 2010040897A1 · 2010 [cited by applicant]
WO WO2014063097A1 · 2014 [cited by examiner]
WO 2017035326A1 · 2017 [cited by applicant]
WO 2017044899A1 · 2017 [cited by applicant]
WO 2017155837A1 · 2017 [cited by applicant]
WO 2018204421A2 · 2018 [cited by applicant]
https://www.ebi.ac.uk/training-beta/online/courses/metabolomics-introduction/what-is/small-molecules/, printed from web Aug. 4, 2020 (Year: 2020). [cited by examiner]
Baughman, R.H. “Solid-state polymerization of diacetylenes.” [cited by applicant]
Blanchette, C.D., et al. “Kinetic Analysis of His-Tagged Protein Binding to Nickel-Chelating Nanolipoprotein Particles.” [cited by applicant]
Fischer, N.O., et al. “Colocalized Delivery of Adjuvant and Antigen Using Nanolipoprotein Particles Enhances the Immune Response to Recombinant Antigens.” [cited by applicant]
Frias, J.C., et al. “Properties of a Versatile Nanoparticle Platform Contrast Agent To Image and Characterize Atherosclerotic Plaques by Magnetic Resonance Imaging.” [cited by applicant]
Georger, J.H., et al. “Helical and Tubular Microstructures Formed by Polymerizable Phosphatidylcholines.” [cited by applicant]
Hayward, J.A., et al. “Biomembrane surfaces as models for polymer design: the potential for haemocompatibility.” [cited by applicant]
Jia, J., et al. “Preparation, Characterizations, and In Vitro Metabolic Processes of Paclitaxel-Loaded Discoidal Recombinant High-Density Lipoproteins.” [cited by applicant]
Johnston, D.S., et al. “Phospholipid Polymers—Synthesis and Spectral Characteristics.” [cited by applicant]
Jonsson, M.P., et al. “Supported Lipid Bilayer Formation and Lipid-Membrane-Mediated Biorecognition Reactions Studied with a New Nanoplasmonic Sensor Template.” [cited by applicant]
Kim, J-M., et al. “Immobilized Polydiacetylene Vesicles on Solid Substrates for Use as Chemosensors.” [cited by applicant]
Lamparski, H., et al. “Two-Dimensional Polymerization of Lipid Bilayers: Degree of Polymerization of Sorbyl Lipids.” [cited by applicant]
Lei, J., et al. “Two-Dimensional Polymerization of Lipid Bilayers: Rate of Polymerization of Acryloyl and Methacryloyl Lipids.” [cited by applicant]
Lieser, G., et al. “Structure, Phase Transitions and Polymerizability of Multilayers of some Diacetylene Monocarboxylic Acids.” [cited by applicant]
Morigaki, K., et al. “Surface Functionalization of a Polymeric Lipid Bilayer for Coupling a Model Biological Membrane with Molecules, Cells, and Microstructures.” [cited by applicant]
Ohno, H., et al. “Polymerization of Liposomes Composed of Diene-Containing Lipids by UV and Radical Initiators: Evidence for the Different Chemical Environment of Diene Groups on 1- and 2-Acyl Chains.” [cited by applicant]
Okazaki, T., et al. “Phase Separation of Lipid Microdomains Controlled by Polymerized Lipid Bilayer Matrices.” [cited by applicant]
Rabinovich, A.L., et al. “On the conformational, physical properties and functions of polyunsaturated acyl chains.” [cited by applicant]
Regen, S.L., et al. “Polymerized Phophatidyl Choline Vesicles. Stabilized and Controllable Time-Release Carriers.” [cited by applicant]
Sadownik, A., et al. “Polymerized Liposomes Formed under Extremely Mild Conditions.” [cited by applicant]
Sells, T.D., et al. “Two-Dimensional Polymerization of Lipid Bilayers: Degree of Polymerization of Acryloyl Lipids.” [cited by applicant]
Serrano, J., et al. “Polymerized Surfactant Vesicles. Determinations of Rates and Degrees of Polymerization in Vesicles Prepared from Styrene-Containing Surfactants.” [cited by applicant]
Shih, A.Y., et al. “Disassembly of Nanodiscs with Cholate.” [cited by applicant]
Tsuchida, E., et al. “Polymerization of Unsaturated Phospholipids as Large Unilamellar Liposomes at Low Temperature.” [cited by applicant]
Aina O.H., et al., “From combinatorial chemistry to cancer-targeting peptides” Mol Pharm, vol. 4, No. 5, pp. 631-651 (2007). [cited by applicant]
Badamchi-Zadeh A, et al., “A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances chlamydia trachomatis clearance.” Frontiers In Immunology, vol. 7, Article 162, pp. 1-11 (Apr. 2016). [cited by applicant]
Baehr W, et al., “Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes.” Proceeding of the National Academy of Sciences, vol. 85, pp. 4000-4004 (1988). [cited by applicant]
Carmichael J.R. et al., “Induction of protection against vaginal shedding and infertility by recombinant Chlamydia vaccine” [cited by applicant]
Chen et al., “Fluorescence Study of Inclusion Complexes between Star-Shaped Cholic Acid Derivatives and Polycyclic Aromatic Fluorescent Probes and the Size Effects of Host and Guest Molecules” Journal of Physical Chemis… [cited by applicant]
Coleman M.A, et al., “Expression and Association of the Yersinia pestis Translocon Proteins, YopB and YopD, Are Facilitated by Nanolipoprotein Particles.” [cited by applicant]
Conlan J, et al., “Isolation of recombinant fragments of the major outer-membrane protein of Chlamydia trachomatis: their potential as subunit vaccines” Microbiology, 136, pp. 2013-2020 (1992). [cited by applicant]
Corrected Notice of Allowance for U.S. Appl. No. 13/719,785, filed Dec. 19, 2012 on behalf of Lawrence Livermore National Laboratory Mail Date: May 23, 2016 5 pages. [cited by applicant]
Dalkara et al., “Intracytoplasmic Delivery of Anionic Proteins” Molecular Therapy, Jun. 2004, vol. 9, No. 6, pp. 964-969. [cited by applicant]
Davidson E, et al., “A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes” Immunology, 143, pp. 13-20 (2014). [cited by applicant]
Duncan R., “Dawning Era of Polymer Therapeutics” Nature Review Drug Discovery vol. 2, No. 5 p. 347-360 (2003). [cited by applicant]
Farris C.M. et al., “CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection” Infection and Immunity, vol. 78, No. 10, pp. 4374-4… [cited by applicant]
Feher V.A. et al., “A 3-dimensional trimeric B-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins.” PloS one p. e68934, vol. 8, Issue 7 (2013). 11 pages. [cited by applicant]
Ferrara L.G.M. et al., “MOMP from Campylobacter jejuni Is a Trimer of 18-Stranded beta-Barrel Monomers with a Ca(2+) Ion Bound at the Constriction Zone.” J Mol Biol (2016), 428(22), pp. 4528-4543. 16 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/499,855, filed Apr. 27, 2017 on behalf of Lawrence Livermore National Laboratory Mail Date: Aug. 8, 2019 11 pages. [cited by applicant]
Findlay H.E, et al., “Surface expression, single-channel analysis and membrane topology of recombinant Chlamydia trachomatis Major Outer Membrane Protein” [cited by applicant]
Ghosh M, et al., “Cationic lipid Nanodisks as an siRNA delivery vehicle” Biochem Cell Biol (2014), 92(3): 200-205. 14 pages. [cited by applicant]
Gref et al., “Biodegradable Long-Circulating Polymeric Nanospheres” Science American Association for the Advancement of Science vol. 263 No. 5153, p. 1600-1603 (1994). [cited by applicant]
Haque F, et al., “Incorporation of a viral DNA-packaging motor channel in lipid bilayers for real-time, single-molecule sensing of chemicals and double-stranded DNA.” Nat Protoc, vol. 8, No. 2, pp. 373-392 (2013). [cited by applicant]
He W, et al., “Cell-free expression of functional receptor tyrosine kinases” [cited by applicant]
He W, et al., “Producing Membrane Bound Proteins as Countermeasures to infectious Diseases” Synthetic Genomics Vaccines (2016). [cited by applicant]
Inic-Kanada A, et al., “A Probiotic Adjuvant Lactobacillus rhamnosus Enhances Specific Immune Responses after Ocular Mucosal Immunization with Chlamydial Polymorphic Membrane Protein C.” PLoS One p. e015785 (2016) 14 pa… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/030537 filed on May 1, 2018 on behalf of Lawrence Livermore National Security. Mail Date: Nov. 14, 2019. 11 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2009/057852, 19 pages, mailed on May 6, 2010. [cited by applicant]
International Search Report and Written Opinion for PCT/US2012/070508, 9 pages, mailed on Feb. 27, 2013. [cited by applicant]
International Search Report for International Application No. PCT/US2018/030537 filed on May 1, 2018 on behalf of Lawrence Livermore National Security Mail Date: Jan. 17, 2019 5 pages. [cited by applicant]
Johnson R.M. et al., “PmpG 303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice.” Infect Immun, vol. 80, No. 6, p. 2204-2211 (2012). [cited by applicant]
Karunakaran K.P. et al., “Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia” J Immunol p. 2459-65 (2008). [cited by applicant]
Karunakaran K.P. et al., “Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.” Vaccine, 33, p. 2159-2166 (2015). [cited by applicant]
Keppetipola S, et al., From gene to HSQC in under five hours: high-throughput NMR proteomics: J Am Chem Soc, 128, pp. 4508-4509 (Apr. 2006). [cited by applicant]
Kigawa T, et al., “Cell-free production and stable-isotope labeling of milligram quantities of proteins” FEBS Lett, 442, pp. 15-19 (Jan. 1999). [cited by applicant]
Klussman S, et al., “The Aptamer Handbook: Functional Oligonucleotides and Their Applications” [cited by applicant]
Koren E, et al., “Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein” Clinical Immunology, 124, pp. 26-32 (2007). [cited by applicant]
Lam K, et al., “A new type of synthetic peptide library for identifying ligand-binding activity” Nature, vol. 354, pp. 82-84 (1991). [cited by applicant]
Levy-Nissenbaum E. et al., “Nanotechnology and aptamers: applications in drug delivery” [cited by applicant]
Li et al., “Antimicrobial Activities of Amine-and Guanidine-Functionalized Cholic Acid Derivatives” Antimicrobial Agents and Chemotherapy vol. 43 (6) p. 1347-1349 (Jun. 1999). [cited by applicant]
Luo et al., “Asymmetric Poly(ethylene glycol) Star Polymers with a Cholic Acid Core and Their Aggregation Properties” Biomacromolecules vol. 10 No. 4 p. 900-906 (2009). [cited by applicant]
Luo J, et al., “Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment.” Bioconjug Chem, 21, pp. 1216-1224 (Jul. 2010). [cited by applicant]
Manning D.S. et al., “Expression of the major outer membrane protein of Chlamydia trachomatis in [cited by applicant]
Mori M, et al., “Cell-free synthesis and processing of a putative precursor for mitochondrial carbamyl phosphate synthetase I of rat liver” Proc Natl Acad Sci USA, vol. 76, No. 10, pp. 5071-5075 (Oct. 1979). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/719,785, filed Dec. 19, 2012 on behalf of Lawrence Livermore National Laboratory Mail Date: Jun. 4, 2015 8 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/499,855, filed Apr. 27, 2017, on behalf of Lawrence Livermore National Security LLC. Mail Date: Jan. 11, 2019. 7 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/719,785, filed Dec. 19, 2012 on behalf of Lawrence Livermore National Laboratory Mail Date: Feb. 17, 2016 7 pages. [cited by applicant]
Pal S, et al., “Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.” Vaccine, 35, p. 2543-2549 … [cited by applicant]
Pal S, et al., “Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge” Infection and Immunity, vol. 65, No. 8, pp. 3361-3… [cited by applicant]
Pal S, et al., “Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge” Infection and immunity, vol. 65, No. 10, pp… [cited by applicant]
Pal S, et al., “Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria” Infection and Immunity, vol. 73,… [cited by applicant]
Ralli-Jain P, et al., “Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.” Vaccine, 28, pp. 7659-7666 (2010). [cited by applicant]
Rensen PC, et al., “Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents.” Mol Pharmacol, 52, pp. 445-455 (Sep. 1997). [cited by applicant]
Rodriguez-Maranon M.J. et al., “Prediction of the membrane-spanning Beta-strands of the major outer membrane protein of Chlamydia” Protein Science, 11, pp. 1854-1861 (2006). [cited by applicant]
Ryan Ro, “Nanobiotechnology applications of reconstituted high density lipoprotein” J Nanobiotechnology, 8:28 (Dec. 2010) 10 pages. [cited by applicant]
Ryan Ro, “Nanodisks: hydrophobic drug delivery vehicles” Expert Opin Drug Deliv., 5(3), pp. 343-351 (Mar. 2008). [cited by applicant]
Semple et al., “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology Feb. 2010, vol. 28, No. 2, pp. 172-176 + 2 additional pages. [cited by applicant]
Su H, et al., “Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein” Journal of Experimental Medicine, vol. 175, pp. 227-235 (1992). [cited by applicant]
Sun G, et al., “Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein” Vaccine, 27, pp. 5020-5025 (2009). [cited by applicant]
Sun G, et al., “Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis” J Bacteriol, vol. 189, No. 17, pp. 6222-6235 (2007). [cited by applicant]
Sunahara H, et al., “Design and synthesis of a library of BODIPY-based environmental polarity sensors utilizing photoinduced electron-transfer-controlled fluorescence ON/OFF switching” J Am Chem Soc., 129, pp. 5597-5604… [cited by applicant]
Tang G, et al., “EMAN2: an extensible image processing suite for electron microscopy” J Struct Biol, 157, pp. 38-46 (2007). [cited by applicant]
Tifrea D.F. et al., “Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine” Vaccine, 29, pp. 4623-4631 (2011). [cited by applicant]
Tifrea D.F. et al., “Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum” The Jo… [cited by applicant]
Tu J, et al., “A multi-epitope vaccine based on Chlamydia trachomatis major outer membrane protein induces specific immunity in mice.” Acta biochimica et biophysica Sinica, vol. 46, Issue 5, pp. 401-408 (2014). [cited by applicant]
Vijayalakshmi et al., “A Simple Construction of a Bile Acid Based Dendritic Light Harvesting System” Organic Letters vol. 7 No. 13 p. 2727-2730 (2005). [cited by applicant]
Wang Y, et al., “Identification of surface-exposed components of MOMP of Chlamydia trachomatis serovar F.” Protein Science, 15, pp. 122-134 (2006). [cited by applicant]
Written Opinion for International Application No. PCT/US2018/030537 filed on May 1, 2018 on behalf of Lawrence Livermore National Security Mail Date: Jan. 17, 2019 9 pages. [cited by applicant]
Xiao et al., “PEG oligocholic acid Telodendrimer micelles for the targeted delivery of doxorubicin to B cell lymphoma” Journal of Controlled Release vol. 155 p. 272-281 (2011). [cited by applicant]
Xiao K, et al., “A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer.” Biomaterials, 30 (30), pp. 6006-6016 (2009) 24 pages. [cited by applicant]
Xiao K, et al., “Telodendrimer-based nanocarriers for the treatment of ovarian cancer.” Ther Deliv, 4(10), pp. 1279-1292 (2013) 24 pages. [cited by applicant]
Yang JP, et al., “Cell-free synthesis of a functional G protein-coupled receptor complexed with nanometer scale bilayer discs.” BMC Biotechnol, 11:57, (May 2011) 8 pages. [cited by applicant]
Zuris J, et al., “Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo” Nature Biotechnology, vol. 33, No. 1, p. 73-80 (2015) 8 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 12/118,530. Mail Date: Jun. 6, 2012, 5 pages. [cited by applicant]
Anantharamaiah, G.M., et al., “Studies of Synthetic Peptide Analogs of the Amphipathic Helix / Structures of Complexes with Dimyristoyl Phosphatidycholine ,” 1985, The Journal of Biological Chemistry, vol. 260, No. 18, … [cited by applicant]
Aranyi T., et al., “Predictable Difficulty or Difficulty to Predict,” [cited by applicant]
Baas B.J., et al., “Homotropic Cooperativity of Monomeric Cytochrome P450 3A4 in a Nanoscale Native Bilayer Environment,” [cited by applicant]
Bacher G., et al., “Negative and Positive Ion Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and Positive Ion Nano-Electrospray Ionization Quadrupole Ion Trap Mass Spectrometry of Peptidogl… [cited by applicant]
Bay et al., “Small multidrug resistance proteins: A multidrug transporter family that continues to grow,” Biochimica et Biophysica Acta 1778 (2008) 1814-1838. [cited by applicant]
Bayburt T.H., et al., “Self-Assembly of Single Integral Membrane Proteins into Soluble Nanoscale Phospholipid Bilayers,” [cited by applicant]
Bayburt T.H., et al., “Single-Molecule Height Measurements on Microsomal Cytochrome P450 in Nanometer-Scale Phospholipid Bilayer Disks,” Proceedings of the National Academy of Sciences of the United States of America, M… [cited by applicant]
Bayburt T.H., et al., “Membrane Protein Assembly into Nanodiscs,” [cited by applicant]
Bayburt T.H., et al., “Transducin Activation by Nanoscale Lipid Bilayers Containing One and Two Rhodopsins,” The Journal of Biological Chemistry, May 2007, vol. 282 (20), 8 pages. [cited by applicant]
Beja O., et al., “Bacterial Rhodopsin: Evidence for a New Type of Phototrophy in the Sea,” [cited by applicant]
Bockaert J., et al., “Do Recombinant Receptor Assays Provide Affinity and Potency Estimates?,” [cited by applicant]
Chung, B.H., et al., “Studies of Synthetic Peptide Analogs of the Amphipathic Helix / Correlation of Structure with Function,” 1985, The Journal of Biological Chemistry, vol. 260, No. 18, 10256-10262. [cited by applicant]
Civjan N., et al., “Direct Solubilization of Heterologously Expressed Membrane Proteins by Incorporation Into Nanoscale Lipid Bilayer,” [cited by applicant]
Cruz F., et al., “Kinetic Properties of Recombinant MAO-A on Incorporation into Phospholipid Nanodisks,” [cited by applicant]
Cullis P.R., et al., “Physical Properties and Functional Roles of Lipids in Membranes,” [cited by applicant]
Dawson P.E., et al., “Synthesis of Native Proteins by Chemical Ligation,” [cited by applicant]
Dengue Fever Climbs the Social Ladder, Special Report, [cited by applicant]
Dong, C., et al., “Regulation of G protein-coupled receptor export trafficking,” Biochimica et Biophysica Acta 1768 (2006) 853-870. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/118,530. Mail Date: Jan. 25, 2012, 37 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/118,530. Mail Date: Mar. 6, 2015, 52 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/469,533. Mail Date: Dec. 4, 2012, 7 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/469,533. Mail Date: Oct. 24, 2011, 11 pages. [cited by applicant]
Frydman J., et al., “Principles of Chaperone-assisted Protein Folding: Differences Between in Vitro and in Vivo Mechanisms,” Science, Jun. 1996, vol. 272 (5267), 6 pages. [cited by applicant]
G Protein-coupled Receptor[online], Retrieved from the Internet: URL: Wikipedia 2008, https://web.archive.org/web/20080224232212/://en.wikipedia.org/wiki/G.protein-coupled.receptor, 2008, 7 pages. [cited by applicant]
Imura, T., et al., “Minimum Amino Acid Residues of an a-Helical Peptide Leading to Lipid Nanodisc Formation,” 2014, J. Oleo Sci. 63, (11) 1203-1208. [cited by applicant]
Imura, T., et al., “Surfactant-like Properties of an Amphilic a-Helical Peptide Leading to Lipid Nanodisc Formation,” 2014, Langmuir, 30, 4752-4759. [cited by applicant]
“Individual” from Merriam-Webster, Jan. 13, 2015, accessed via WayBackMachine.com (2 pages). [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2008/063307, Mail Date: Nov. 10, 2009, 7 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2016/051172 filed Sep. 9, 2016 on behalf of Lawrence Livermore National Security, LLC. Mail Date: Mar. 13, 2018. 8 pages. (English Only). [cited by applicant]
International Search Report for Application No. PCT/US2008/063307, Mail Date: Oct. 29, 2008, 5 pages. [cited by applicant]
International Search Report for Application No. PCT/US2016/051172, Mail Date: Dec. 13, 2016., 6 pages. [cited by applicant]
“Ion channel”, Wikipedia, accessed Dec. 22, 2014, pp. 1-8, 8 pages. [cited by applicant]
Ishihara G., et al., “Expression of G Protein Coupled Receptors in a Cell-free Translational System Using Detergents and Thioredoxin-fusion Vectors,” [cited by applicant]
Jonas A., “Defined Apolipoprotein A-I Conformations in Reconstituted High Density Lipoprotein Discs,” [cited by applicant]
Jonas A., “Reconstitution of High-density Lipoproteins,” Methods in Enzymology, 1986, vol. 128, 7 pages. [cited by applicant]
Jones M.K., et al., “Computer Programs to Identify and Classify Amphipathic alpha Helical Domains,” Journal of Lipid Research, Feb. 1992, vol. 33 (2), 287-296. 10 pages. [cited by applicant]
Klammt C., et al., “Cell-free Production of G Protein-coupled Receptors for Functional and Structural Studies,” [cited by applicant]
Lam K.S., et al., “Application of Combinatorial Library Methods in Cancer Research and Drug Discovery,” Anti-cancer Drug Design, Apr. 1997, vol. 12 (3), 145-167. 24 pages. [cited by applicant]
“Microsome” from Wikipedia, Mar. 3, 2008, accessed via WayBackMachine.com (1 page). [cited by applicant]
Midtgaard, S.R., et al., “Self-assembling peptides form nanodiscs that stabilize membrane proteins,” 2014, Soft Matter, 10, 738-752. [cited by applicant]
Nanodisc Trademark #78166119, Owner: Sligar, Stephen G., Retrieved from the Internet:[URL:https://inventively.com/search/trademarks/78166119], retrieved on Aug. 4, 2015, 2 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/118,530. Mail Date: Aug. 30, 2011, 28 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/118,530. Mail Date: Jul. 24, 2014, 33 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/469,533. Mail Date: May 23, 2012, 15 pages. [cited by applicant]
North P., et al., “Alteration of Synaptic Membrane Cholesterol/Phospholipid Ratio Using a Lipid Transfer Protein, Effect on Gamma-aminobutyric Acid Uptake,” [cited by applicant]
Notice of Allowance for U.S. Appl. No. 12/469,533. Mail Date: Jul. 3, 2014, 13 pages. [cited by applicant]
Pasini E.M., et al., “In-Depth Analysis of the Membranes and Cytosolic Proteome of Red Blood Cells,” Blood, Aug. 2006, vol. 180 (3), 12 pages. [cited by applicant]
Patel J.D., et al., “Preparation and Characterization of Nickel Nanoparticles for Binding to His-Tag Proteins and Antigens,” [cited by applicant]
Peters-Libeau C.A., et al., “Model of Biologically Active Apolipoprotein E Bound to Dipalmitoylphosphatidylcholine,” [cited by applicant]
Restriction Requirement for U.S. Appl. No. 12/118,530, filed May 9, 2008. Mail Date: Sep. 24, 2010, 14 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 12/118,530. Mail Date: Mar. 30, 2011, 10 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 12/469,533. Mail Date: Jun. 7, 2011, 8 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 15/744,754, filed Jan. 12, 2018 on behalf of Lawrence Livermore National Laboratory Mail Date: Aug. 7, 2019 9 pages. [cited by applicant]
Rüger R., et al., “In Vitro Characterization of Binding and Stability of Single-Chain Fv Ni-NTA-Liposomes,” [cited by applicant]
Sawasaki T., et al., “A Bilayer Cell-Free Protein Synthesis System for High-Throughput Screening of Gene Products,” [cited by applicant]
Schmitt L., et al., “Synthesis and Characterization of Chelator-Lipids for Reversible Immobilization of Engineered Proteins at Self-Assembled Lipid Interfaces,” [cited by applicant]
Segota S., et al., “Spontaneous Formation of Vesicles,” [cited by applicant]
Shaw A.W., et al., “Phospholipid Phase Transitions in Homogeneous Nanometer Scale Bilayer Discs,” [cited by applicant]
Shih A.Y., et al., “Molecular Dynamics Simulations of Discoidal Bilayers Assembled from Truncated Human Lipoproteins,” [cited by applicant]
Sligar, S., “Overview of Nanodisc Technology” from Sligar Lab, accessed Nov. 21, 2014 (1 page). [cited by applicant]
Sligar webpage http://sligarlab.life.uiuc.edu/nanodisc.html, accessed Feb. 28, 2018. “Nanodisc Technology: Soluble Lipid Bilayer Systems for Structural and Functional Studies of Membrane Proteins” (3 pages). [cited by applicant]
Sperling R.A., et al., “Surface Modification, Functionalization and Bloconjugation of Colloidal Inorganic Nanoparticles,” Philosophical Transactions of the Royal Society A, Mar. 2010, vol. 368, 1333-1383, 51 pages. [cited by applicant]
Sun P.D., et al., “Overview of Protein Structural and Functional Folds,” [cited by applicant]
Svetina S., et al., “Shape Behavior of Lipid Vesicles as the Basis of Some Cellular Processes,” The Anatomical Record, Nov. 2002, vol. 268 (3), 215-225. 11 pages. [cited by applicant]
Toniolo C. et al., “Lipopeptaibols, a novel family of membrane active, antimicrobial peptides” [cited by applicant]
Tufteland M., et al., “Peptide Stabilized Amphotericin B Nanodisks,” [cited by applicant]
“Vesicle” from Wikipedia, Dec. 16, 2008, accessed via WayBackMachine.com (5 pages). [cited by applicant]
Wallin E., et al., “Genome-Wide Analysis of Integral Membrane Proteins from Eubacterial, Archaean, and Eukaryotic Organisms,” [cited by applicant]
Whorton M.R., et al., “A Monomeric G Protein-Coupled Receptor Isolated in a High-Density Lipoprotein Particle Efficiently Activates its G Protein,” Proceedings of the National Academy of Sciences, May 2007, vol. 104 (18… [cited by applicant]
Written Opinion for Application No. PCT/US2008/063307, Mail Date: Oct. 29, 2008, 6 pages. [cited by applicant]
Written Opinion for Application No. PCT/US2016/051172, Mail Date: Dec. 13, 2016, 7 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/499,855, filed Apr. 27, 2017 on behalf of Lawrence Livermore National Security, LLC. Mail Date: Dec. 31, 2019. 3 pages. [cited by applicant]
De Filippis et al., “Enhanced Protein Thermostability by Ala → Aib Replacement,” [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/744,754, filed Jan. 12, 2018 on behalf of Lawrence Livermore National Laboratory. Mail Date: Mar. 4, 2020. 53 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/082,924, filed Sep. 6, 2018 on behalf of Lawrence Livermore National Security, LLC. Mail Date: Jan. 31, 2020 25 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/499,855, filed Apr. 27, 2017 on behalf of Lawrence Livermore National Security, LLC. Mail Date: Mar. 5, 2020. 43 Pages. [cited by applicant]
PDB database search for oxysterol binding protein, retrieved from the Internet: <http://www.rcsb.org/pdb/results/results.do?tabtoshow=Current&amp;qrid=37B93383>, retrieved onFeb. 20, 2020. 7 Pages. [cited by applicant]
Reinau M. et al. “The Diversity of FtsY-Lipid Interactions” [cited by applicant]
Ruchala et al., “Oxpholipin 11D: An Anti-Inflammatory Peptide That Binds Cholesterol and Oxidized Phospholipids,” PLoS One, Apr. 2010, vol. 5, Issue 4, e10181. 13 pages. [cited by applicant]
Adamczyk J., et al., “The Isotope Array, a New Tool That Employs Substrate-Mediated Labeling of rRNA for Determination of Microbial Community Structure and Function,”. [cited by applicant]
Adams, M.W.W., et al., “Hydrogenase,” 1981, Biochimica et Biophysica Acta 594, 105-176. [cited by applicant]
Addison S.L., et al., “Stable Isotope Probing: Technical Considerations When Resolving (15)N-labeled RNA in Gradients,” [cited by applicant]
Bayburt T.H., et al., “Self-Assembly of Discoidal Phospholipid Bilayer Nanoparticles with Membrane Scaffold Proteins,” Nano Letters, 2002, vol. 2 (8), 4 pages. [cited by applicant]
Boldog T., et al., “Nanodiscs Separate Chemoreceptor Oligomeric States and Reveal Their Signalling Properties,” [cited by applicant]
Boldog T., et al., “Using Nanodiscs to Create Water-soluble Transmembrane Chemoreceptors Inserted in Lipid Bilayer,” [cited by applicant]
Brodie E.L., et al., “Urban Aerosols Harbor Diverse and Dynamic Bacterial Populations,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 2007, vol. 104 (1), 299-304. 6 pages. [cited by applicant]
Burgdorf T., et al., “The Soluble NAD+-Reducing [NiFe]-Hydrogenase from Ralstonia eutropha H16 Consists of Six Subunits and can be Specifically Activated by NADPH,” Journal of Bacteriology, May 2005, vol. 187 (9), 3122-… [cited by applicant]
Casey P.J., et al., “Protein Prenyltransferases,” [cited by applicant]
Chefson A., et al., “Progress Towards the Easier Use of P450 Enzymes,” [cited by applicant]
Choquet C.G., et al., “Stability of Pressure-extruded Liposomes Made From Archaeobacterial Ether Lipids,” [cited by applicant]
Cornish K., et al., “Characterization of Cis-Prenyl Transferase Activity Localised in a Buoyant Fraction of Rubber Particles From Ficus Elastica Latex,” [cited by applicant]
Cornish K., et al., “Natural Rubber biosynthesis in Plants: Rubber Transferase,” Methods in Enzymology, 2012, vol. 515, 63-82. 20 pages. [cited by applicant]
Cornish K., et al., “Rubber Biosynthesis in Plants,” American Oil Chemist Society, [cited by applicant]
Das D., et al., “Role of Fe-hydrogenase in Biological Hydrogen Production,” Current Science, Jun. 2006, vol. 90 (12), 1627-1637. 11 pages. [cited by applicant]
Denisov, I.G., et al., “Cytochromes P450 in Nanodiscs,” Biochimica et Biophysica Act, 2010, 7 pages. [cited by applicant]
Donninger C., et al., “An Improved Synthesis of Isopentenyl Pyrophosphate,” The Biochemical Journal, Nov. 1967, vol. 105 (2), 545-547. 3 pages. [cited by applicant]
Dubey R., et al., “Microencapsulation Technology and Applications,” Defence Science Journal, Jan. 2009, vol. 59 (1), 82-95. 14 pages. [cited by applicant]
Elgren T. E. et al., “Immobilization of Active Hydrogenases by Encapsulation in Polymeric Porous Gels,” [cited by applicant]
Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Jun. 7, 2012, 25 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Jun. 29, 2015, 18 pages. [cited by applicant]
Friedrich T. et al., “The respiratory complex I of bacteria, archaea and eukarya and its module common with membrane-bound multisubunit hydrogenases.” FEBS Lett. Aug. 2000 11;479(1-2):1-5. [cited by applicant]
Gan L., et al., “Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b-5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes,” [cited by applicant]
Gilbert L., “Insect Development: Morphognesis, molting and Metamorphosis,” [cited by applicant]
Gorrod J.W., et al., “Some Observations on Type I and Type II Microsomal Binding Spectra,” [cited by applicant]
Greve, H-H., “Rubber, 2. Natural” in [cited by applicant]
Grinkova, Y.V., et al., “Engineering extended membrane scaffold proteins for self-assembly of soluble nanoscale lipid bilayers,” Protein Engineering, Design and Selection, 2010, vol. 23, No. 11, pp. 843-848. [cited by applicant]
Gronover C.S., et al., “Natural Rubber Biosynthesis and Physics-Chemical Studies on Plant Derived Latex,” [cited by applicant]
Hallenbeck P.C. et al., “Biological Hydrogen Production: Fundamentals and Limiting Processes,” [cited by applicant]
Hasemann C.A., et al., “Structure and Function of Cytochromes P450: a Comparative Analysis of Three Crystal Structures,” [cited by applicant]
Hein C.D., et al., “Click Chemistry, A Powerful Tool for Pharmaceutical Sciences,” [cited by applicant]
Hiraishi T., et al., “Enzyme-catalyzed Synthesis and Degradation of Biopolymers,” [cited by applicant]
Ho D., et al., “Fabrication of Biomolecule-copolymer Hybrid Nanovesicles as Energy Conversion Systems,” [cited by applicant]
Kurkin S., et al., “The Membrane-bound [NiFe]-hydrogenase (Ech) From Methanosarcina Barkeri: Unusual Properties of the Iron-sulphur Clusters,” [cited by applicant]
Lechene C., et al., “High-resolution Quantitative Imaging of Mammalian and Bacterial Cells Using Stable Isotope Mass Spectrometry,” [cited by applicant]
Leitz A.J., et al., “Functional Reconstitution of Beta2-adrenergic Receptors Utilizing Self-assembling Nanodisc Technology,” [cited by applicant]
Long M., et al., “Characterization of a HoxEFUYH type of [NiFe] Hydrogenase from Allochromatium Vinosum and Some EPR and IR Properties of the Hydrogenase Module,” [cited by applicant]
McIntosh C.L., et al., “The [NiFe]-Hydrogenase of the [cited by applicant]
McTernan P.M., et al., “Intact Functional Fourteen-Subunit Respiratory Membrane-Bound [NiFe]-Hydrogenase Complex of the Hyperthermophilic Archaeon Pyrococcus Furiosus,” [cited by applicant]
Meuer J., et al., “Purification and Catalytic Properties of Ech Hydrogenase From Methanosarcina Barkeri,” [cited by applicant]
Meyer J., “[Fe/Fe] Hydrogenases and Their Evolution: A Genomic Perspective,” [cited by applicant]
Nath A et al., “Applications of Phospholipid Bilayer Nanodiscs in the Study of Membranes and Membrane Proteins,” Biochemistry, Feb. 2007, vol. 46 (8), 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Aug. 12, 2016, 31 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Dec. 26, 2014, 24 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Oct. 2, 2013, 19 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/352,472. Mail Date: Sep. 22, 2011, 21 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/352,548. Mail Date: Sep. 13, 2011, 19 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/536,513. Mail Date: Mar. 24, 2016, 19 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 12/352,472. Mail Date: Mar. 17, 2017, 12 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 12/352,548. Mail Date: Apr. 25, 2014, 9 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 12/352,548. Mail Date: Aug. 5, 2014, 8 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 12/352,548. Mail Date: Mar. 12, 2012, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/536,513. Mail Date: Jul. 14, 2016, 5 pages. [cited by applicant]
Ohya N., et al., “Biosynthesis of Natural Rubber and Other Natural Polyisoprenoids,” Biopolymers Polyisoprenoids, Jan. 2005, 73-81. 9 pages. [cited by applicant]
Pan Z., et al., “The Major Protein of Guayule Rubber Particles is a Cytochrome P450: Characterization based on cDNA Cloning and Spectroscopic Analysis of the Solubilized Enzyme and Its Reaction Products,” The Journal of… [cited by applicant]
Paterson-Jones J.C., et al., “The Biosynthesis of Natural Rubber,” Journal of Plant Physiology, Jun. 1990, vol. 136 (3), 7 pages. [cited by applicant]
Persson B., et al., “Topology Prediction of Membrane Proteins,” Protein Science, Feb. 1996, vol. 5 (2), 9 pages. [cited by applicant]
Ponciano G., et al., “Transcriptome and Gene Expression Analysis in Cold-Acclimated Guayule ( [cited by applicant]
Rakhely G., et al., “Cyanobacterial-Type, Heteropentameric, NAD+-Reducing NiFe Hydrogenase in the Purple Sulfur Photosynthetic Bacterium Thiocapsa Roseopersicina,” Applied and Environmental Microbiology, Feb. 2004, vol.… [cited by applicant]
Rapp V. et al., “Predicting Fuel Performance for Future HCCI Engines” Combust. Sci. Technol., 185: 735-748, Apr. 20, 2013. 15 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 12/352,472. Mail Date: May 27, 2011, 8 pages. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 12/352,548. Mail Date: Apr. 25, 2011, 6 pages. [cited by applicant]
Sabatini, D.D., et al., “Mechanisms for the Incorporation of Proteins in Membranes and Organelles,” Jan. 1, 1982, The Journal of Cell Biology, vol. 92, 1-22. [cited by applicant]
Sanderson K., “Chemistry: The Photon Trap,” Nature, Mar. 27, 2008, vol. 452(7186), 3 pages. [cited by applicant]
Sapra R., et al., “A Simple Energy-Conserving System: Proton Reduction Coupled to Proton Translocation,” Proceedings of the National Academy of Sciences of the United States of America, Jun. 24, 2003, vol. 100(13), 6 pa… [cited by applicant]
Sapra R., et al., “Purification and Characterization of a Membrane-Bound Hydrogenase from the Hyperthermophilic Archaeon Pyrococcus Furiosus,” Journal of Bacteriology, Jun. 2000, vol. 182(12), 6 pages. [cited by applicant]
Schmidt T., et al., “Characterization of Rubber Particles and Rubber Chain Elongation in Taraxacum Koksaghyz,” BMC Biochemistry, Feb. 19, 2010, vol. 11, 11 pages. [cited by applicant]
Schmitz O., et al., “HoxE—A Subunit Specific for the Pentameric Bidirectional Hydrogenase Complex (HoxEFUYH) of Cyanobacteria,” Biochimica et Biophysica Acta, Apr. 22, 2002, vol. 1554(1-2), 9 pages. [cited by applicant]
Siler D.J., et al., “Composition of Rubber Particles of Hevea Brasiliensis, Parthenium Argentatum, Ficus Elastics and Euphorbia Lactiflua Indicates Unconventional Surface Structure,” Plant Physiology and Biochemistry, J… [cited by applicant]
Silvius J.R., “Thermotropic Phase Transitions of Pure Lipids in Model Membranes and their Modification by Membrane Proteins,” Lipid-Protein Interactions, 1982, vol. 2, pp. 239-281, 43 pages. [cited by applicant]
Singer, S.J., et al., “The Fluid Mosaic Model of the Structure of Cell Membranes,” Feb. 1972, Science, vol. 175, 720-731. [cited by applicant]
Singh A.P., et al., “The Micromorphology and Protein Characterization of Rubber Particles in Ficus Carica, Ficus Benghalensis and Hevea Brasiliensis,” Journal of Experimental Botany, Mar. 2003, vol. 54 (384), 8 pages. [cited by applicant]
Smith D. et al., “Solubilisation of methane monooxygenase from [cited by applicant]
Soboh B., et al., “Purification and Catalytic Properties of a CO-Oxidizing: H2-Evolving Enzyme Complex from Carboxydothermus Hydrogenoformans,” European Journal of Biochemistry, Nov. 2002, vol. 269 (22), 10 pages. [cited by applicant]
Stadermann F.J., et al., “Nanosims: The Next Generation Ion Probe for the Microanalysis of ExtraTerrestrial Material,” Meteoritics and Planetary Science, 36342, vol. 34 (4), 1999. 2 pages. [cited by applicant]
Stryer L., et al., “Oxygen Binds to a Heme Prosthetic Group: Biochemistry,” 1995, 4th edition, 1 page. [cited by applicant]
Vincent K. A., et al., “Electrocatalytic Hydrogen Oxidation by an Enzyme at High Carbon Monoxide or Oxygen Levels,” [cited by applicant]
Vincent K. A., et al., “Investigating and Exploiting the Electrocatalytic Properties of Hydrogenases,” [cited by applicant]
Whalen M., et al., “Development of Crops to Produce Industrially Useful Natural Rubber,” [cited by applicant]
White, S., Membrane Protein Insertion: The Biology-Physics Nexus, Apr. 16, 2007, J. Gen. Physiol., vol. 129, No. 5, 363-369. [cited by applicant]
Wikipedia—Bacteriorhodopsin, 2 pages, (Downloaded from the internet on Jun. 22, 2015). [cited by applicant]
Wikipedia., Hydrogenase retrieved from en.wikipedia.org/wiki/Hydrogenase on Nov. 6, 2012, 4 pages. [cited by applicant]
Woodward J., et al., “Enzymatic Production of Biohydrogen,” [cited by applicant]
Woodward J., et al., “In Vitro Hydrogen Production by Glucose Dehydrogenase and Hydrogenase,” [cited by applicant]
Wu, L., et al., “Membrane targeting and translocation of bacterial hydrogenases,” 2000, Arch Microbiology, 173:319-324. [cited by applicant]
Xie W., et al., “Initiation of Rubber Biosynthesis: In Vitro Comparisons of Benzophenone-Modified Diphosphate Analogues in Three Rubber-Producing Species,” [cited by applicant]
Zhang Y.H., et al., “High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway,” [cited by applicant]
Zhanhua C., et al., “Protein Subunit Interfaces: Heterodimers versus Homodimers,” [cited by applicant]
Akkaladevi, N., et al., Assembly of Anthrax Toxin Pore: Lethal-Factor Complexes into Lipid Nanodiscs, Protein Science, vol. 22, pp. 492-501, (2013). [cited by applicant]
Allen, T.M., et al., “Drug Delivery Systems: Entering the Mainstream.”, Science, vol. 303(5665), pp. 1818-1822, (2004), 6 pages. [cited by applicant]
Baylon, J.L., et al., “Characterizing the Membrane-Bound State of Cytochrome P450 3A4: Structure, Depth of Insertion, and Orientation.”, Journal of the American Chemical Society, 135(23), pp. 8542-8551, (2013), 11 pages. [cited by applicant]
Bhattacharya, P., et al., “Nanodisc-Incorporated Hemagglutinin Provides Protective Immunity against Influenza Virus Infection.”, Journal of Virology, 84(1), pp. 361-371, (2010). [cited by applicant]
Blanchette, C.D., et al., “Atomic Force Microscopy Differentiates Discrete Size Distributions Between Membrane Protein Containing and Empty Nanolipoprotein Particles.”, Biochimica et Biophysica Acta (BBA)-Biomembranes, … [cited by applicant]
Blanchette, C.D., et al., “Characterization and Purification of Polydisperse Reconstituted Lipoproteins and Nanolipoprotein Particles.”, International Journal of Molecular Sciences, 10(7), pp. 2958-2971, (2009). [cited by applicant]
Blanchette, C.D., et al., “Quantifying Size Distributions of Nanolipoprotein Particles with Single-Particle Analysis and Molecular Dynamic Simulations.”, Journal of Lipid Research, 49(7), pp. 1420-1430, (2008), 12 pages. [cited by applicant]
Bolikal, D., et al., “Degree of Polymerization of a Vesicle Membrane.”, Macromolecules, 17(6), pp. 1287-1289, (1984). [cited by applicant]
Cappuccio, J.A., et al., “Cell-Free Expression for Nanolipoprotein Particles: Building a High-Throughput Membrane Protein Solubility Platform.”, High Throughout Protein Expression and Purification, Springer, pp. 273-295… [cited by applicant]
Cappuccio, J.A., et al., “Cell-Free Co-Expression of Functional Membrane Proteins and Apolipoprotein, Forming Soluble Nanolipoprotein Particles.”, Molecular & Cellular Proteomics, 7(11), pp. 2246-2253, (2008). [cited by applicant]
Cho, K., et al., “Therapeutic Nanoparticles for Drug Delivery in Cancer.”, Clinical Cancer Research, 14(5), pp. 1310-1316, (2008), 8 pages. [cited by applicant]
Chromy, B.A., et al., “Different Apolipoproteins Impact Nanolipoprotein Particle Formation.”, Journal of the American Chemical Society, vol. 129, No. 46, pp. 14348-14354, (2007). [cited by applicant]
Das, A., et al., “Screening of Type I and II Drug Binding to Human Cytochrome P450-3A4 in Nanodiscs by Localized Surface Plasmon Resonance Spectroscopy.”, Analytical Chemistry, 81(10), pp. 3754-3759, (2009), 14 pages. [cited by applicant]
Fischer, N.O., et al., “Conjugation to Nickel-Chelating Nanolipoprotein Particles Increases the Potency and Efficacy of Subunit Vaccines to Prevent West Nile Encephalitis.”, Bioconjugate Chemistry, 21(6), pp. 1018-1022,… [cited by applicant]
Fischer, N.O., et al., “Evaluation of Nanolipoprotein Particles (NLPs) as an In Vivo Delivery Platform.”, Plos One, 9(3), e93342, (2014), 17 pages. [cited by applicant]
Fischer, N. O., et al., “Immobilization of His-Tagged Proteins on Nickel-Chelating Nanolipoprotein Particles.” Bioconjugate Chemistry, vol. 20, No. 3, pp. 460-465, (2009). [cited by applicant]
Fischer, N. O., et al., “Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with Apolipophor in-III.” PLOS one, Jul. 2010, vol. 5, No. 7, e11643, 10 pages. [cited by applicant]
Gao, T.J., et al., “Characterization of De Novo Synthesized GPCRs Supported in Nanolipoprotein Discs.”, PLoS One, 7(9), e44911, (2012), 8 pages. [cited by applicant]
Gao, T.J., et al., “Characterizing Diffusion Dynamics of a Membrane Protein Associated with Nanolipoproteins Using Fluorescence Correlation Spectroscopy.”, Protein Science, 20(2), pp. 437-447, (2011). [cited by applicant]
Justesen, B.H., et al., “Isolation of Monodisperse Nanodisc-Reconstituted Membrane Proteins Using Free Flow Electrophoresis.”, Analytical Chemistry, 85(7), pp. 3497-3500, (2013), 5 pages. [cited by applicant]
Katzen, F. et al., “Insertion of Membrane Proteins into Discoidal Membranes Using a Cell-Free Protein Expression Approach.”, Journal of Proteome Research, 7(8), pp. 3535-3542, (2008). [cited by applicant]
Mao, H., et al., “Design and Characterization of Immobilized Enzymes in Microfluidic Systems.”, Analytical Chemistry, 74(2), pp. 379-385, (2002). [cited by applicant]
Miyazaki, M., et al., “Effect of Phospholipid Composition on Discoidal HDL Formation.”, Biochimica et Biophysica Acta, 1828(5), pp. 1340-1346. (2013). [cited by applicant]
Okahata, Y., et al., “Polymerizable Lipid-Corked Capsule Membranes. Polymerization at Different Positions of Corking Lipid Bilayers on the Capsule and Effect of Polymerization on Permeation Behavior.” Journal of the Ame… [cited by applicant]
Pavlidou, M., et al., “Nanodiscs Allow Phage Display Selection for Ligands to Non-Linear Epitopes on Membrane Proteins.”, PLoS One, 8(9), (2013), 8 pages. [cited by applicant]
Portet, T., et al., “A New Method for Measuring Edge Tensions and Stability of Lipid Bilayers: Effect of Membrane Composition.”, Biophysical Journal, vol. 99, pp. 3264-3273, (2010). [cited by applicant]
Rawicz, W., et al., “Effect of Chain Length and Unsaturation on Elasticity of Lipid Bilayers.”, Biophysical Journal, vol. 79(1), pp. 328-339, (2000). [cited by applicant]